• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 23, 2020

View Archived Issues
RNA and SARS-CoV-2 virus cell

Translate Bio stock rockets as Sanofi expands into mRNA platform for vaccines

DUBLIN – Translate Bio Inc. is the first beneficiary to gain from Sanofi SA’s massive $11.7 billion addition to its balance sheet, following its recent disposal of its holdings in long-time partner Regeneron Pharmaceuticals Inc. Lexington, Mass.-based Translate Bio is getting $300 million up front, another $125 million in equity investment and up to $1.9 billion in milestones under a major expansion of an existing agreement with Paris-based Sanofi to develop mRNA-based vaccines for infectious disease. Read More

Pionyr’s deal with Gilead could bring in more than $1B

Gilead Sciences Inc. has acquired a 49.9% equity interest in privately held Pionyr Immunotherapeutics Inc., which could receive up to $1.15 billion in potential future milestone payments in the deal. Read More
AI-digital-health.png

Artificial intelligence strategies being implemented by biopharma companies

The importance of artificial intelligence and machine learning continues to be acknowledged by drug development companies. Recently, to help accelerate the discovery of therapies to treat COVID-19, several deals have been forged to deploy those tools. Read More

Taking immunotherapy to the next level

Bolstered by the success of CTLA4 and PD-(L)1 antibodies, companies are exploring new targets to encourage the immune system to attack tumors. "While these agents have demonstrated efficacy in a proportion of cancer patients, there clearly is room for improvement to lift the tail of the curve," Michele Teng, associate professor at the QIMR Berghofer Medical Research Institute, told the audience at the clinical trials plenary session of the American Association for Cancer Research Virtual Annual Meeting II, where researchers presented data from a pair of immunotherapies looking to build on the success targeting PD-(L)1. Read More
Connected drug capsules

Combination therapies: Searching for synergy

Almost all solid tumors are treated with multiple drugs because the combinations have better efficacy than single-agent treatments. But finding those combinations can be difficult in an ever-growing sea of pair-wise combinations. Read More
Coronavirus vs US

Pandemic-weary nation prepares for next COVID-19 wave

The bad news is, yes, the U.S. is in for a second wave of COVID-19, which is expected to hit during the upcoming flu season. The good news is the nation is much better prepared for the next wave, the NIH’s Anthony Fauci told a House Energy and Commerce Committee Tuesday. Read More
US-Washington-congress-senate-house.png

Witnesses at Senate hearing press for annual appropriation for vaccine infrastructure

The Senate Health, Education, Labor and Pensions (HELP) Committee met again June 23 to discuss the federal government response to the COVID-19 pandemic, and one clear signal that emerged from the hearing is that Congress will have to provide annual funding to build a sustainable infrastructure for vaccine development and manufacture if the nation is to deal appropriately with the next pandemic. Read More
Gloved hand holding COVID-19 vaccine vial, syringe

South Korea’s Genexine begins phase I/IIa trials for COVID-19 vaccine

HONG KONG – South Korea-based Genexine Inc. has started enrolling a phase I/II trial for a DNA vaccine targeting COVID-19 called GX-19. Read More

Appointments and advancements for June 23, 2020

New hires and promotions in the biopharma industry, including: Adma, Athenex, Avid, Bioxcel, Catalyst, Storm, Xortx. Read More

Conference data for June 23, 2020: American Association for Cancer Research

New and updated preclinical and clinical data presented by biopharma firms at AACR Virtual Annual Meeting II, including: Allogene, Beyondspring, Cue, Jaguar, Medigene, Mersana, Molecular Templates, Neoleukin, Nimbus, Nkarta, Oric, Phio, Puretech, Rgenix, Rubryc, Silverback, Sotio, Spectrum, Sutro, TG, Theratechnologies, Tolero, Tonix, Transgene, Turning Point, Twoxar, Tyme, VBI Vaccines, VBL, Verastem, Xencor. Read More

Financings for June 23, 2020

Biopharmas raising money in public or private financings, including: Castle Biosciences, Catalyst Biosciences, Greenwich Lifesciences, Iveric Bio, Leap, Outlook, Sana, Saniona, Silence, Tara Biosystems. Read More

In the clinic for June 23, 2020

Clinical updates, including trial initiations, enrollment status and data readouts and publications: ABM, Achilles, Bioinvent, Fibrogen, Kadmon, Myovant, Oncolytics, Oppilan, Principio, Reneo, Seelos, Sunesis, Vaccitech. Read More

Other news to note for June 23, 2020

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aligos, Alphabet, Amgen, Avita, Biosig, Brainstorm, Catalent, CARB-X, Century Therapeutics, Daiichi Sankyo, Empirica, Everest, Frontier Scientific, Gilead, Illumina, Inovio, Itm Isotopen, Leo Lens, Linnaeus, Millendo, Miragen, Novartis, Palatin, Scenic, Schrödinger, Takeda, Teligent, Thermo Fisher Renibus, Viralclear, Wuxi Apptech. Read More

Regulatory actions for June 23, 2020

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Immunovative, Mirror Biologics, Karuna, Karyopharm, Marker, Myovant, Novaremed, Pharmacyclics, Polynoma, Reneo, Renibus, Santhera. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 9, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe